DBC vs XBI
Invesco DB Commodity Index Tracking Fund vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.85% for DBC.
- • DBC pays a higher dividend yield (2.40%).
Side-by-side metrics
| Metric | DBC | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.85% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.40% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $1.89B | $8.30B |
YTD return | 35.11% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.02 | 1.09 |
P/E ratio | 7.32 | — |
Last price | $30.25 | $133.66 |
Inception | — | — |
Issuer | Invesco | State Street |
DBC top holdings
| AGPXX | Invesco Shrt-Trm Inv Gov&Agcy Instl | 41.56% |
| BRNU26 | Brent Crude Future July 26 | 9.67% |
| TBLL | Invesco Short Term Treasury ETF | 6.02% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About DBC
DBC (Invesco DB Commodity Index Tracking Fund) is Diversified commodity basket. Managed by Invesco, the fund carries $1.9B in assets under management, an expense ratio of 0.85%, a dividend yield of 2.40%. Its largest holding is Invesco Shrt-Trm Inv Gov&Agcy Instl (AGPXX), which represents 41.6% of the portfolio.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.